Decoy Therapeutics Announces That One Of Its D-MAV Candidates Demonstrates In Vitro Activity Against Wild-Type Ebola Zaire Virus
Building on the result, Decoy has opened an exploratory program to design D-MAVs against filoviruses, including Ebola and Marburg. The candidate was engineered on Decoy's IMP3ACT™ platform to block coronavirus
Decoy Therapeutics created a new medicine candidate that worked against Ebola virus in lab tests. This shows their science approach might help fight dangerous viruses, so watch if they keep making progress on this new program.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.